FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3178704504> ?p ?o ?g. }

• W3178704504 abstract "50 Years after the generation of the most studied human breast cancer cell line, MCF-7, many research results fundamentally changed patient outcomes for the better. The mortality of breast cancer in women has decreased significantly, especially in the last 30 years. But the total number of deaths is rising again in the last ten years. Considering that breast cancer is the most common cancer in women and the second most common cancer overall, with incidences of 24,2% and 11,6%, respectively, total numbers of new cases are in the millions every year.First line drugs for the treatment of breast cancer often target microtubules (e.g. Vinblastine and Paclitaxel) or induce DNA damage (e.g. Carboplatin and Cisplatin (CisPt)). In addition to these classic therapeutic drugs new compounds that specifically target cancer-driving molecular alterations have been developed. Among these is the group of BH3-mimetics. The efficacy of several BH3-mimetics is investigated in numerous clinical trials while the BCL-2 specific inhibitor ABT-199 (Venetoclax) is already approved for clinical application in chronic lymphatic leukemia (CLL), acute myeloid leukemia (AML) and small lymphocytic lymphoma (SLL). BH3-mimetics target the apoptosis machinery by interacting with anti-apoptotic Bcl-2 proteins, mimicking the function of pro-apoptotic BH3-only proteins. In turn, the pro-apoptotic potential of pore-forming BCL-2 effectors BAX, BAK and BOK is released inducing mitochondrial outer membrane permeabilization and cell death.Recently we reported synergistic cell death induction by ABT-199 in combination with the proteasome inhibitor Bortezomib (BOZ) in soft tissue sarcoma (STS) cells. ABT-199 and BOZ induce accumulation of BOK and the BH3-only protein NOXA (Muenchow et al. 2020). Here, we combined ABT-199, CisPt and Nutlin-3 in breast cancer cell lines that differ in expression of the estrogen receptor (ER) and p53 activity. Similar to the results in STS cells synergistic induction of apoptotic cell death was observed by FACS analysis of the mitochondrial membrane potential (TMRM) and exposure of phosphatidyl serine (Annexin-V). Western blot analysis revealed that ABT-199 induced accumulation of NOXA and MCL-1, irrespective of the ER status or p53 mutation. Simultaneous treatment with ABT-199 and CisPt or Nutlin-3 further increased expression of NOXA and MCL-1. Interestingly, qRT-PCR revealed enhanced expression of NOXA and MCL-1 mRNA in ABT-199 treated cells indicating transcriptional regulation. However, transcriptional induction of NOXA was also detected independent of p53 activity. Thus, combined therapeutic approaches using CisPt and ABT-199 should be effective irrespective of ER and p53 expression. Nevertheless, in p53 proficient tumors Nutlins might increase therapeutic efficacy.Citation Format: Benjamin Schaefer, Sandra Weller, Tobias Beigl, Kathrin Boepple, Reiner Hoppe, Klaus Schulze-Osthoff, Hans-Georg Kopp, Walter E. Aulitzky, Frank Essmann. Synergistic cell death induction in breast cancer cell lines by combining ABT-199 and cisplatin irrespective of estrogen receptor and p53 expression [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 1946." @default.
• W3178704504 created "2021-07-19" @default.
• W3178704504 creator A5003011876 @default.
• W3178704504 creator A5005870156 @default.
• W3178704504 creator A5014714915 @default.
• W3178704504 creator A5036009814 @default.
• W3178704504 creator A5047674033 @default.
• W3178704504 creator A5065763995 @default.
• W3178704504 creator A5066952869 @default.
• W3178704504 creator A5074047222 @default.
• W3178704504 creator A5091873260 @default.
• W3178704504 date "2021-07-01" @default.
• W3178704504 modified "2023-10-15" @default.
• W3178704504 title "Abstract 1946: Synergistic cell death induction in breast cancer cell lines by combining ABT-199 and cisplatin irrespective of estrogen receptor and p53 expression" @default.
• W3178704504 doi "https://doi.org/10.1158/1538-7445.am2021-1946" @default.
• W3178704504 hasPublicationYear "2021" @default.
• W3178704504 type Work @default.
• W3178704504 sameAs 3178704504 @default.
• W3178704504 citedByCount "0" @default.
• W3178704504 crossrefType "proceedings-article" @default.
• W3178704504 hasAuthorship W3178704504A5003011876 @default.
• W3178704504 hasAuthorship W3178704504A5005870156 @default.
• W3178704504 hasAuthorship W3178704504A5014714915 @default.
• W3178704504 hasAuthorship W3178704504A5036009814 @default.
• W3178704504 hasAuthorship W3178704504A5047674033 @default.
• W3178704504 hasAuthorship W3178704504A5065763995 @default.
• W3178704504 hasAuthorship W3178704504A5066952869 @default.
• W3178704504 hasAuthorship W3178704504A5074047222 @default.
• W3178704504 hasAuthorship W3178704504A5091873260 @default.
• W3178704504 hasConcept C121608353 @default.
• W3178704504 hasConcept C126322002 @default.
• W3178704504 hasConcept C190283241 @default.
• W3178704504 hasConcept C2776364478 @default.
• W3178704504 hasConcept C2776694085 @default.
• W3178704504 hasConcept C2777132456 @default.
• W3178704504 hasConcept C2777292972 @default.
• W3178704504 hasConcept C2777478702 @default.
• W3178704504 hasConcept C2777938653 @default.
• W3178704504 hasConcept C2778239845 @default.
• W3178704504 hasConcept C2778367456 @default.
• W3178704504 hasConcept C2778461978 @default.
• W3178704504 hasConcept C2779675984 @default.
• W3178704504 hasConcept C2781451048 @default.
• W3178704504 hasConcept C31573885 @default.
• W3178704504 hasConcept C502942594 @default.
• W3178704504 hasConcept C530470458 @default.
• W3178704504 hasConcept C55493867 @default.
• W3178704504 hasConcept C71924100 @default.
• W3178704504 hasConcept C86803240 @default.
• W3178704504 hasConcept C96232424 @default.
• W3178704504 hasConcept C98274493 @default.
• W3178704504 hasConceptScore W3178704504C121608353 @default.
• W3178704504 hasConceptScore W3178704504C126322002 @default.
• W3178704504 hasConceptScore W3178704504C190283241 @default.
• W3178704504 hasConceptScore W3178704504C2776364478 @default.
• W3178704504 hasConceptScore W3178704504C2776694085 @default.
• W3178704504 hasConceptScore W3178704504C2777132456 @default.
• W3178704504 hasConceptScore W3178704504C2777292972 @default.
• W3178704504 hasConceptScore W3178704504C2777478702 @default.
• W3178704504 hasConceptScore W3178704504C2777938653 @default.
• W3178704504 hasConceptScore W3178704504C2778239845 @default.
• W3178704504 hasConceptScore W3178704504C2778367456 @default.
• W3178704504 hasConceptScore W3178704504C2778461978 @default.
• W3178704504 hasConceptScore W3178704504C2779675984 @default.
• W3178704504 hasConceptScore W3178704504C2781451048 @default.
• W3178704504 hasConceptScore W3178704504C31573885 @default.
• W3178704504 hasConceptScore W3178704504C502942594 @default.
• W3178704504 hasConceptScore W3178704504C530470458 @default.
• W3178704504 hasConceptScore W3178704504C55493867 @default.
• W3178704504 hasConceptScore W3178704504C71924100 @default.
• W3178704504 hasConceptScore W3178704504C86803240 @default.
• W3178704504 hasConceptScore W3178704504C96232424 @default.
• W3178704504 hasConceptScore W3178704504C98274493 @default.
• W3178704504 hasLocation W31787045041 @default.
• W3178704504 hasOpenAccess W3178704504 @default.
• W3178704504 hasPrimaryLocation W31787045041 @default.
• W3178704504 hasRelatedWork W1224191223 @default.
• W3178704504 hasRelatedWork W2010684987 @default.
• W3178704504 hasRelatedWork W2017065239 @default.
• W3178704504 hasRelatedWork W2094661349 @default.
• W3178704504 hasRelatedWork W2157431139 @default.
• W3178704504 hasRelatedWork W2364024683 @default.
• W3178704504 hasRelatedWork W2379373882 @default.
• W3178704504 hasRelatedWork W2389825807 @default.
• W3178704504 hasRelatedWork W2409808170 @default.
• W3178704504 hasRelatedWork W2992820193 @default.
• W3178704504 isParatext "false" @default.
• W3178704504 isRetracted "false" @default.
• W3178704504 magId "3178704504" @default.
• W3178704504 workType "article" @default.